Roberts Caroline G P, Athinarayanan Shaminie J, Ratner Robert E, Umpierrez Guillermo E
Virta Health, Denver, Colorado, USA.
Department of Medicine, Division of Endocrinology, Georgetown University School of Medicine, Washington, District of Columbia, USA.
Diabetes Obes Metab. 2025 May;27(5):2531-2539. doi: 10.1111/dom.16252. Epub 2025 Feb 25.
Ketogenic diets are used by individuals with obesity and type 2 diabetes for improved glycaemic control, reduced appetite and weight loss. However, the risks associated with higher ketone levels, including diabetic ketoacidosis (DKA), in individuals with and without diabetes are not well-documented.
We analysed real world data from a single-centre telemedicine clinic specializing in a very low carbohydrate ketogenic diet (VLCKD) as a lifestyle intervention. Illnesses associated with ketosis (IAK) were defined as beta-hydroxybutyrate (BHB) levels ≥3 mmol/L when patients sought in-person care. We estimated the IAK and DKA incidence rate in individuals with and without type 2 diabetes.
In 72 751 patient-years of follow-up, 86 people had IAK (incidence rate 1.18 per 1000 person-years). In 22 347 patient-years of follow-up of people without diabetes, the incidence rate of IAK was 0.04 per 1000 person-years with no DKA cases. In 50 404 patient-years of follow-up in people with type 2 diabetes (PWD), the incidence rates of IAK and of DKA were 1.69 and 1.01 per 1000 person-years, respectively. In 12 763 person-years of follow-up of PWD using SGLT2-inhibitors, the DKA incidence was 2.90 per 1000 patient-years.
Very low carbohydrate ketogenic diets are generally safe with low rates of IAK, including DKA, in people with and without type 2 diabetes. The higher incidence of DKA in PWD on VLCKD who are also on SGLT2-inhibitors may be manageable through at-home monitoring of BHB levels.
肥胖和2型糖尿病患者采用生酮饮食以改善血糖控制、降低食欲并减轻体重。然而,无论有无糖尿病,与较高酮水平相关的风险,包括糖尿病酮症酸中毒(DKA),尚未得到充分记录。
我们分析了来自一家单中心远程医疗诊所的真实世界数据,该诊所专门采用极低碳水化合物生酮饮食(VLCKD)作为一种生活方式干预措施。当患者寻求面对面护理时,与酮症相关的疾病(IAK)被定义为β-羟基丁酸(BHB)水平≥3 mmol/L。我们估计了有无2型糖尿病个体的IAK和DKA发病率。
在72751患者年的随访中,86人发生IAK(发病率为每1000人年1.18例)。在22347患者年的非糖尿病患者随访中,IAK发病率为每1000人年0.04例,无DKA病例。在50404患者年的2型糖尿病患者(PWD)随访中,IAK和DKA的发病率分别为每1000人年1.69例和1.01例。在12763患者年的使用钠-葡萄糖协同转运蛋白2抑制剂(SGLT2-inhibitors)的PWD随访中,DKA发病率为每1000患者年2.90例。
极低碳水化合物生酮饮食总体上是安全的,在有无2型糖尿病的人群中,包括DKA在内的IAK发生率较低。对于同时使用SGLT2抑制剂的VLCKD饮食的PWD患者,通过在家监测BHB水平,较高的DKA发病率可能是可控的。